Trial Outcomes & Findings for Tear Film Break-up Time After Instillation of Artificial Tears (NCT NCT00681265)

NCT ID: NCT00681265

Last Updated: 2012-10-26

Results Overview

State-of-the-art methodology to assess tear stability.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

16 participants

Primary outcome timeframe

15 minutes after eye drop instillation

Results posted on

2012-10-26

Participant Flow

Dates: 5/18/2008 to 8/30/2008. Single site: Flaum Eye Institute at the University of Rochester.

Participant milestones

Participant milestones
Measure
Glycerin Eye Drop / PEG 400 and Propylene Glycol Eye Drop
One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient. The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
Overall Study
STARTED
16
Overall Study
COMPLETED
16
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Tear Film Break-up Time After Instillation of Artificial Tears

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Glycerin Eye Drop / PEG 400 and Propylene Glycol Eye Drop
n=16 Participants
One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient. The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
16 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age Continuous
44.5 years
STANDARD_DEVIATION 10.8 • n=5 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
Sex: Female, Male
Male
6 Participants
n=5 Participants
Region of Enrollment
United States
16 participants
n=5 Participants

PRIMARY outcome

Timeframe: 15 minutes after eye drop instillation

Population: Study N determined empirically by PI.

State-of-the-art methodology to assess tear stability.

Outcome measures

Outcome measures
Measure
New Formulation of Glycerin 1% Eye Drop
n=16 Participants
One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
Propylene Glycol and PEG 400 Eye Drop
n=16 Participants
The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
Noninvasive Tear Film Break-up Time
14.67 seconds
Standard Deviation 27.21
7.4 seconds
Standard Deviation 30.30

SECONDARY outcome

Timeframe: 120 minutes after eye drops instillation

Population: Study N determined empirically by PI.

Standard clinical assessment methodology for assessing tear stability.

Outcome measures

Outcome measures
Measure
New Formulation of Glycerin 1% Eye Drop
n=16 Participants
One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
Propylene Glycol and PEG 400 Eye Drop
n=16 Participants
The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
Fluorescein Tear Film Break-up Time
11.13 seconds
Standard Deviation 12.08
6.21 seconds
Standard Deviation 4.86

Adverse Events

New Formulation of Glycerin 1% Eye Drop

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Propylene Glycol and PEG 400 Eye Drop

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David M. Kleinman

Eyeon Therapeutics, Inc.

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place